ABSTRACT
INTRODUCTION
Herpes simplex virus Type 1 (HHV1) is a double-stranded DNA virus in the Herpesviridae family. Worldwide prevalence of HHV1 infection was estimated in 2012 to be 67% with highest prevalence in Africa, South-East Asia and Western Pacific (Looker et al. 2015) . HHV1 is mainly transmitted by oral-oral contact causing oral herpes (cold sores) and genital herpes. The infection is asymptomatic but can lead to chronic or latent infection and end with fatality (Roizman et al. 2006) . Acylovir (ACV) is the common antiviral agent used to treat HHV1 infection but drug resistance has developed in immunocompromised patients prophylactically treated with ACV for extended periods (Piret & Boivin 2011) . ACV inhibits HHV1 replication by serving as a substrate for the viral DNA polymerase reaction that leads to the formation of incomplete DNA complex (Reardon & Spector 1989) . Resistance towards ACV can develop by frameshift mutations or nucleotide substitutions in the thymidine kinase (TK) viral gene resulting in different phenotypes (Gilbert et al. 2002) . Thus, it is essential to develop new antiviral agents with a different mechanism of action from ACV. Plants are important sources of antiviral lead molecules and Eleusine indica has been reported to have antiviral activity (Iberahim et al. 2016 (Iberahim et al. , 2015 Tahir et al. 2014) . Eleusine indica is an invasive grass species in the family Poaceae and has been used as folk remedy for skin problems. It has been indicated with antioxidant and anti-inflammatory activities (Sagnia et al. 2014 ). The methanol extract of E. indica is safe to cells (Iberahim et al. 2015) , protect cells against viral infection, inhibits viral attachment and penetration and also has virucidal effect (Iberahim et al. 2016 ). This study was done to further determine the compounds in E. indica methanol extract and elucidate the antiviral effect with regards to in vitro inhibition of different stages of HHV1 replication and progeny infectivity.
MATERIALS AND METHODS

PLANT MATERIAL
Methanol extract of E. indica was prepared according to Iberahim et al. (2015) . For antiviral treatment, a stock solution of 10 mg/mL was prepared by sonication of the extract in 1%, w/v DMSO and 99%, v/v of Dulbecco Modified Essential Medium (DMEM, Gibco. USA).
CELLS AND VIRUS
African green monkey kidney cells (Vero cells) and a clinical strain of HHV1 were obtained from the Virology Laboratory, Universiti Kebangsaan Malaysia stock collection. Vero cells were grown in DMEM supplemented with 5%, v/v Fetal Bovine Serum (FBS, Jr. Scientific. USA), 100 U/L of penicillin/streptomycin (Gibco. USA), non-essential amino acid (Gibco. USA 100×) and 20 U/L of amphostate B (Sigma-Aldich, USA). Cell culture was maintained in an incubator at 37°C and humidified with 5% CO 2 atmosphere. Virus titer was estimated using a standard plaque assay as described by Blaho et al. (2006) .
LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS) ANALYSIS
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) analysis of the E. indica methanol extract was performed on AB Sciex LCMSMS 3200QTrap system coupled to AgilentLC/MDSTrap VL for negative ionisation modes. Spectrum data with graph peaks between 100 and 700 nm was recorded and processed by LCMSD software for data acquisition and analysis.
TIME-OF-ADDITION ASSAY
The assay was followed as previously described by Cheng et al. (2006) . Monolayer cells were infected with 100 pfu of virus and incubated at 37°C for 2 h. Eleusine indica methanol extract (0.3 mg/mL) was added at 2, 4, 6, 8 or 10 h post infection (hpi) followed by the addition of 1% methyl cellulose (MCS). Cells were further incubated at 37°C until 24 hpi. Plaques were stained with crystal violet solution (0.4%, w/v) and the percentage of plaques inhibition was calculated using the following formula:
The assay was done according to the procedure of Zhen et al. (2006) with modification of removal time. Confluent monolayers of Vero cell were infected with 100 pfu of HHV1 for 2 h at 37°C. Methanol extract of E. indica (0.3 mg/mL) was added to the infected cells immediately after treatment. Medium containing the methanol extract was removed at 2, 4, 8, 10, 12, 14, 16, 18, 20, 22 and 24 hpi, cells were washed twice with DMEM without FBS for one min and replaced with 1% MCS. Cells were further incubated for 48 h before staining with crystal violet solution (0.4%). The percentage of plaque inhibition was calculated using the formula as above.
VIRUS YIELD REDUCTION ASSAY
The assay was done according to the procedure by Saddi et al. (2007) with slight modification in the concentration used. Cells were infected with HHV1 at multiplicity of infection (MOI) = 1 for 2 h at 37°C. Infected cells were treated with different concentrations of methanol extract (0.1, 0.2, 0.3 and 0.4 mg/mL) and further incubated at 37°C for 10 h. At the end of the incubation, infected cells were frozen at -80°C and thawed for five min repeatedly for three times. This was to ensure that virus in the infected cells stopped replicating. Cells were detached from wells by sonication for 15 min and the virus collected by centrifugation in the supernatant. The percentage of plaque inhibition by the virus released by the cells was titrated and calculated as above.
QUANTITATIVE REAL TIME -POLYMERASE CHAIN REACTION (QRT-PCR)
Quantitative RT-PCR was performed to determine the effect of E. indica methanol extract on the transcription of selected HHV1 genes at different replication stages. Confluent cells were infected with HHV1 at 0.1 MOI, treated with 0.3 mg/mL extract and the infected cells removed at 2, 8, 12, 20 and 24 hpi. Viral RNA was extracted using viral RNA extraction kit (Tetra Viral RNA kit) and subjected to reverse transcription by Tetro cDNA treatment kit. The specific primers for qRT-PCR are listed in Table 1 which represented all three phases of HHV1 life cycle: Immediate early phase (U L 54), early phase (U L 30), late phase (U L 27); and housekeeping genes coding for Cyclophilin A and RPL-32. Quantitative PCR (qPCR) was performed on a real-time PCR machine (Biorad iQ5, Invitrogen Life Science Technologies) using the following conditions: polymerase enzyme activation at 95°C for 10 min, followed by annealing process for 40 cycles at 95°C for 15 s and elongation at 60°C for 1 min followed by a final melt curve analysis using instrument default settings. Gene expression of all the three genes in methanol extract-treated virus relative to the expression in non-treated virus was calculated for each time point. Positive and negative controls were included in all runs.
IMMUNOFLUORESCENT STAINING
Confluent cells were seeded on confocal slits and virus infected at 0.1 MOI. Extract (0.3 mg/mL) was added and incubated at 4°C for 90 min. After incubation, cells were washed with phosphate buffered saline (PBS), followed by fixation in 4% paraformaldehyde for 30 min at room temperature (RT) and incubation with methanol at 20°C for 10 min. Cells were washed three times with PBS and followed by incubation with PBS-Triton X-FBS (PBTF) for 10 min at RT. Cells were washed once with PBTF and blocked with FBS 10% for 90 to 120 min. Virus glycoprotein staining for gB, gC and gD was done by adding primary antibodies (anti-gB, anti-gC and anti-gD) in PBTF for 4 h at RT. This is then followed by addition of secondary antibody conjugated with fluorescein isothiocyanate (FITC). Nucleus was stained with 4', 6-diamidino-2-phenylindole (DAPI). Images were viewed at three random fields in two technical replicates for each treatment using a confocal microscope (Olympus ix2 ill 100).
RESULTS
COMPOUNDS IN E. INDICA METHANOL EXTRACT
Thirty eight compounds were separated and determined by LC-MS/MS analysis from the E. indica methanol extract but only 12 compounds were identified ( Table 2) . Most of the compounds are from the flavonoid and phenolic groups. Several compounds found in the extract have been previously described as having antiviral activity. For example, Nakama et al. (2012) reported that caffeic acid inactivates HHV1 by blocking viral attachment and penetration into the host cell. Antraquinones display virucidal effect on enveloped virus such as HHV1 (Sydiskis et al. 1991 ) and naringenin showed a moderate antiviral effect towards HHV1 (Lyu et al. 2005) . The direct effect of E. indica methanol extract on the virus has been reported by Iberahim et al. (2016) that hampered virus absorption. In this study, polyphenols are present in the methanol extract as shown in the LC-MS/MS analysis. Contribution of this polyphenols to the virucidal activity is yet to be confirmed. Hydroxybenzoic acid derivatives in the presence of other compounds were able to inhibit 68.1% of plaque formation in HHV1 infection (Kamel et al. 2010 ). In addition, the methanol extract may also contain cytoprotective, antioxidant and anti-inflammatory substances (Table 2) .
ELEUSINE INDICA IS EFFECTIVE DURING EARLY STAGE OF HHV1 REPLICATION
Time-of-addition assay was performed to determine the effect of E. indica when added at different times beginning from the time of infection and at 2 h interval until 10 hpi. Figure 1 shows that 75% of plaque inhibition occurred when E. indica was added during the first 2 h post infection and declined to more than 50% at 6 hpi. This observation is parallel to the results in our previous study which showed that E. indica prevented virus attachment and penetration (Iberahim et al. 2016 ) which represent the early stage of HHV1 replication cycle. Time-removal assay was conducted from the beginning of infection (2 hpi) until the end of late phase in HHV1 replication cycle (26 hpi). Plaque inhibition (40%) occurred starting from 2 hpi to 79% inhibition at 12 hpi (Figure 2 ). Decrease in plaque inhibition occurred after 12 to 20 hpi at 39% but increased to 73% at 24 hpi. This implies that E. indica inhibits the attachment, penetration and early phase of virus replication as indicated in the timeof-addition assay but does not affect progeny packaging or late phase of virus replication. However, the extract was able to alter and reduce the level of infectivity in progeny that is released from the infected cells as observed at 24 hpi. To further confirm this observation, virus yield reduction assay was performed.
ELEUSINE INDICA REDUCES VIRUS YIELD AND PROGENY INFECTIVITY
Virus-infected cultures were incubated with E. indica methanol extract for a period sufficient to permit virus replication and assayed for the presence of new progeny virus by titration on separate monolayer cultures. Figure  3 shows that the progeny infectivity was reduced to 43% using 0.3 mg/mL extract after 10 h of treatment and dosedependent. The virucidal activity of E. indica methanol extract has been indicated previously (Iberahim et al. 2016) . Furthermore, virus reinfection may have been reduced due to the modification of the released progeny by exposure to the extract thus inhibiting the attachment and penetration into cells. Antiproliferative and apoptogenic effects (Philchenkov & Zavelevych 2015) FIGURE 1. The effect of E. indica methanol extract on plaque inhibition in time-of-addition assay Treatment with E. indica at 2 hpi causes down regulation of U L 27 transcription in the immediate early phase. Down regulation of all three genes by the treatment was observed at 8 hpi (early replication phase) but at 12 hpi, only U L 54 and U L 27 genes were up-regulated. At 20 hpi (late phase when viral progeny is estimated to be released), all three genes were transcribed and not affected by the treatment. However, at 24 hpi, the transcription levels for U L 30 and U L 27 genes were up-regulated but U L 54 gene was downregulated to less than 2 fold change relative to the nontreated infected cell.
ELEUSINE INDICA INHIBITS MAINLY GLYCOPROTEIN B BUT NOT GLYCOPROTEIN C AND D
The effect of E. indica on the attachment process involving virus glycoproteins gB, gC and gD in immunofluorescent staining of infected and treated cells is showed in Figure  5 . Reduced gB expression was observed when treated with E. indica compared to non-treated samples ( Figure 5 
DISCUSSION
In general, one replication cycle of HHV1 will be completed within 10 to 12 h (Honess & Roizman 1974) . In this study, the virus showed visible plaques as early as 28 h of infection. Plaque formation inhibition activity was demonstrated beginning from the time point when the virus attaches to the cell until the release of new progeny. From the time-removal assay, the percentage of plaque inhibition All three viral genes were down-regulated at 8 hpi and with obvious downregulation of U L 54 (4-fold change). At 12 hpi only U L 30 was down-regulated but not U L 54 and U L 30 (but less than 1-fold change). All the three genes were highly up-regulated more that 3-fold change compared to the initial value. At 24 hpi, only U L 54 was down-regulated increased from 2 until 12 hpi and slightly reduced until 20 hpi. This indicates that treatment with E. indica affects all phases of viral replication. Effect of treatment with E. indica however was more noted during early and late phases indicated by more than 50% of plaque formation inhibition. These results are parallel to the inhibition of expression of U L 54, U L 30 and U L 27 genes in qRT-PCR assay. In a normal HHV1 replication cycle, all respective genes will be up-regulated throughout the phases (Wagner et al. 2010) . Specifically, U L 54 was expressed increasingly throughout the replication phases and as early as 2 hpi. For U L 30 that codes for DNA polymerase, transcription reached the maximum level during 5 to 7 hpi. As for U L 27, higher transcription was noted in the late phase compared to the immediate early phase (Wagner et al. 2010 ). According to Kratz et al. (2008) , inhibition of the immediate early phases can be due to the modification and disruption of cell receptor and viral glycoproteins during attachment and entry of virus. In this study, U L 54 gene was chosen due to the observation by Wagner et al. (2010) that any changes to the expression level of this gene can affect the functions of other early and late genes including gC for viral attachment. In addition, U L 54 is responsible in increasing DNA replication (Rice & Knipe 1990) and increasing the transcription of the late genes (Uprichard & Knipe 1996) . Treatment with E. indica caused upregulation to more than 1 fold change of U L 54 and U L 30 expressions during immediate early phase. Treatment with E. indica however did not alter the expression of gC as shown in the immunocytochemistry assay. Thus, the up-regulation of U L 54 in immediate early phase does not affect the gC expression. Even though gC is not responsible directly for viral penetration, inhibition of it will generally reduce viral infection (Shukla & Spear 2001) . As for the U L 27 gene that codes for gB, downregulation of more than 2 fold and parallel to the inhibition of gB expression were noted in the immunocytochemistry assay. Glycoprotein B is one of the important viral proteins responsible for the attachment and entry of virus into the cell (Spear & Longnecker 2003) . To confirm the antiviral activity in an attachment assay carried out previously (Iberahim et al. 2015) , the inhibition of gD was also studied. The penetration process of virus into a cell depends on the interaction between gD with other related glycoproteins such as gB, gH and gL at a certain amount (Butcher et al. 1990 ). On the other hand, incomplete formation of gD-gB-gH-gL complex could cause failure of the penetration process (Turner et al. 1998) . From the results obtained, it can be concluded that the inhibition of viral attachment and penetration by E. indica was not caused by gD inhibition. The most possible explanation on the ability of E. indica to cause failure to virus attachment is the down-regulation of gB expression which affects the formation of gD-gB-gH-gL complex. Down-regulation in UL 27 and subsequent reduction in gB expression have also been observed in an experiment using the treatment of a HHV inhibitor PHA767491 (Hou et al. 2017) .
In HHV1 replication, U L 30, U L 54 and U L 27 genes will be up-regulated throughout the phases. For early phase of virus replication at around 8 to 12 hpi, expression of U L 30 gene was observed due to its function in viral DNA replication. This activity takes place in the nucleus and is closely related to U L 54 transcription (Wagner et al. 2010) . At 8 hpi, treatment with E. indica causes all three genes to be down-regulated. However, at 12 hpi U L 30 expression continues to be down-regulated but U L 54 and U L 27 were slightly up-regulated by up to 2 fold change relative to non-treated virus infected cells. In short, expression of the early phase genes was down-regulated by E. indica extract at 8 hpi but does not affect U L 54 and U L 27 at 12 hpi.
During the late phase of replication, all three genes were up-regulated reaching 3 to 13 fold change in treated and virus infected cells compared to the non-treated virus infected cells. However by 24 hpi, i.e. when it is estimated to be the time when the virus progeny is being released, down-regulation of U L 54 and U L 27 was noted. This is parallel to the results from the time-removal assay that demonstrated increase in plaque formation inhibition at 24 and 26 hpi. Since it was noted previously that E. indica can be virucidal, inhibit virus attachment and penetration (Iberahim et al. 2016) , continuous treatment prevents progeny from being released as supported by the results in virus yield and progeny infectivity. The downregulation of U L 54 gene noted in this study may affect the progeny from causing infection to neighbouring cells.
CONCLUSION
The methanol extract of E. indica contains different pharmacologically active substances which demonstrate a multifacet process in intervention of the different steps of the virus replication phases. The extract also provided protection to cells from virus reinfection where progeny infectivity was reduced mainly by modification of the gB protein. Treatment with E. indica is effective at all HHV1 replication phases but more pronounced during early and late phases. It is proposed that E. indica methanol extract be further evaluated in vivo for its therapeutic potential as an anti-HSV agent.
